Jana Portnow, MD
Enriched profileProfessor, Department of Medical Oncology and Therapeutics Research; Co-Director, Brain Tumor Program, City of Hope · City of Hope
Jana Portnow is Professor, Department of Medical Oncology and Therapeutics Research; Co-Director, Brain Tumor Program, City of Hope at City of Hope. OpenAlex indexes 149 publications with 9,814 citations (h-index 32); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 12 Oct 2026
Overview
Updated 16 Oct 2026
Jana Portnow, MD, is Professor, Department of Medical Oncology and Therapeutics Research at City of Hope. The public record shows 149 publications with 9,814 citations (h-index 32), centered on Glioma Diagnosis and Treatment, Immunotherapy and Immune Responses, CAR-T cell therapy research. It also documents an investigator role on 18 registered clinical trials, 5 NIH-funded awards (2006–2026).
- Most recent indexed publication: 2026 · Neuro-oncology
- Top research focus: Glioma Diagnosis and Treatment
- 18 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 46.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Sponsor: Diakonos Oncology Corporation
- Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
Sponsor: City of Hope Medical Center
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
21.5%Salt solutions21.5%Sodium Chloride100%Part D<11 patientsCancer & immunology
20.1%Aromatase Inhibitor10.4%Anastrozole100%Part D<11 patientsKinase inhibitor9.7%Ibrance100%Part D<11 patientsSensory organs
18.8%Corticosteroid18.8%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
5 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
Beckman Research Institute/city of Hope
FY2026$680,856U19CA264512 - Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
Beckman Research Institute/city of Hope
FY2025$925,385U19CA264512
Congress activity
Updated 16 Oct 2026
23 congress contributions (2005–2026) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 2296: Liquid biopsy of cerebrospinal fluid in breast to brain metastases
AACR Annual Meeting
AACR2024Co-author - Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas.
ASCO Annual Meeting
ASCO2024Presenting authorPosterTrials in progress
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.
Clinical cancer research
Clinical Trial2025 - Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Journal of clinical oncology
Guideline2022
Most-cited works
by citation count (OpenAlex)- 01Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyArticle1,841 citations2016
- 02
- 03
- 04Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyArticle544 citations2020
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jana-portnow-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/city-of-hope_targeting-glioblastoma-with-a-cancer-killing-activity-7038644679348785152-vHl0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Editorial & leadership roles
journal and society appointments- Vice Chair
NCCN Guidelines Panel for Central Nervous System Cancers
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗ - Member
NIH Clinical Oncology Study Section
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hope Rugo, MD
City of Hope
Amandeep Salhotra, MD
City of Hope
Amrita Krishnan, MD
City of Hope
James Ito, MD
City of Hope
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
David Reardon, MD
Dana-Farber Cancer Institute